These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 31471540)
1. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Wang Y; Wenzl K; Manske MK; Asmann YW; Sarangi V; Greipp PT; Krull JE; Hartert K; He R; Feldman AL; Maurer MJ; Slager SL; Nowakowski GS; Habermann TM; Witzig TE; Link BK; Ansell SM; Cerhan JR; Novak AJ Blood Cancer J; 2019 Aug; 9(9):73. PubMed ID: 31471540 [TBL] [Abstract][Full Text] [Related]
2. DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation. Xue X; Huang W; Qiu T; Guo L; Ying J; Lv N BMC Cancer; 2020 Aug; 20(1):816. PubMed ID: 32854650 [TBL] [Abstract][Full Text] [Related]
3. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Green MR; Monti S; Rodig SJ; Juszczynski P; Currie T; O'Donnell E; Chapuy B; Takeyama K; Neuberg D; Golub TR; Kutok JL; Shipp MA Blood; 2010 Oct; 116(17):3268-77. PubMed ID: 20628145 [TBL] [Abstract][Full Text] [Related]
4. High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma. Sebastián E; Alcoceba M; Martín-García D; Blanco Ó; Sanchez-Barba M; Balanzategui A; Marín L; Montes-Moreno S; González-Barca E; Pardal E; Jiménez C; García-Álvarez M; Clot G; Carracedo Á; Gutiérrez NC; Sarasquete ME; Chillón C; Corral R; Prieto-Conde MI; Caballero MD; Salaverria I; García-Sanz R; González M Ann Hematol; 2016 Jan; 95(2):253-62. PubMed ID: 26573278 [TBL] [Abstract][Full Text] [Related]
5. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma. Huang S; Nong L; Liang L; Zheng Y; Wang W; Liu J; Li D; Li X; Wang Y; Zhang B; Li T Cancer Med; 2019 Jul; 8(8):3831-3845. PubMed ID: 31150165 [TBL] [Abstract][Full Text] [Related]
6. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Georgiou K; Chen L; Berglund M; Ren W; de Miranda NF; Lisboa S; Fangazio M; Zhu S; Hou Y; Wu K; Fang W; Wang X; Meng B; Zhang L; Zeng Y; Bhagat G; Nordenskjöld M; Sundström C; Enblad G; Dalla-Favera R; Zhang H; Teixeira MR; Pasqualucci L; Peng R; Pan-Hammarström Q Blood; 2016 Jun; 127(24):3026-34. PubMed ID: 27030389 [TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185 [TBL] [Abstract][Full Text] [Related]
13. Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis. Scholtysik R; Kreuz M; Hummel M; Rosolowski M; Szczepanowski M; Klapper W; Loeffler M; Trümper L; Siebert R; Küppers R; Int J Cancer; 2015 Mar; 136(5):1033-42. PubMed ID: 25042405 [TBL] [Abstract][Full Text] [Related]
14. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer. Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930 [TBL] [Abstract][Full Text] [Related]
15. Primary mediastinal (thymic) large B-cell lymphoma: a short review with brief discussion of mediastinal gray zone lymphoma. Hutchinson CB; Wang E Arch Pathol Lab Med; 2011 Mar; 135(3):394-8. PubMed ID: 21366467 [TBL] [Abstract][Full Text] [Related]
16. Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. Yuan J; Wright G; Rosenwald A; Steidl C; Gascoyne RD; Connors JM; Mottok A; Weisenburger DD; Greiner TC; Fu K; Smith L; Rimsza LM; Jaffe ES; Campo E; Martinez A; Delabie J; Braziel RM; Cook JR; Ott G; Vose JM; Staudt LM; Chan WC; Am J Surg Pathol; 2015 Oct; 39(10):1322-30. PubMed ID: 26135560 [TBL] [Abstract][Full Text] [Related]
17. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. Gupta S; Cheville JC; Jungbluth AA; Zhang Y; Zhang L; Chen YB; Tickoo SK; Fine SW; Gopalan A; Al-Ahmadie HA; Sirintrapun SJ; Blum KA; Lohse CM; Hakimi AA; Thompson RH; Leibovich BC; Berger MF; Arcila ME; Ross DS; Ladanyi M; Antonescu CR; Reuter VE Mod Pathol; 2019 Sep; 32(9):1344-1358. PubMed ID: 30996253 [TBL] [Abstract][Full Text] [Related]
18. Current and emerging treatment options in primary mediastinal B-cell lymphoma. Fakhri B; Ai W Ther Adv Hematol; 2021; 12():20406207211048959. PubMed ID: 34659697 [TBL] [Abstract][Full Text] [Related]
19. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Shi M; Roemer MG; Chapuy B; Liao X; Sun H; Pinkus GS; Shipp MA; Freeman GJ; Rodig SJ Am J Surg Pathol; 2014 Dec; 38(12):1715-23. PubMed ID: 25025450 [TBL] [Abstract][Full Text] [Related]
20. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Twa DD; Chan FC; Ben-Neriah S; Woolcock BW; Mottok A; Tan KL; Slack GW; Gunawardana J; Lim RS; McPherson AW; Kridel R; Telenius A; Scott DW; Savage KJ; Shah SP; Gascoyne RD; Steidl C Blood; 2014 Mar; 123(13):2062-5. PubMed ID: 24497532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]